European Pharmacovigilance Congress 2024

18-19 November 2024
Online
English
 
22 November 2024
Face-to-Face in Milan
English
 

Conference overview

The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences.
EUPV congress is proud to have high quality scientific content as its main characteristic which has attracted growing interest from speakers, sponsors and participants from all over the world.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors,) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
To further improve the value of the congress and continuously make it more and more interesting by bringing new ideas and scientific contents, this year the  Scientific Advisory Group has been further widened with the addition of new PV key opinion leaders who need no introduction since their knowledge and skills are world class.
EUPV congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.

Congress Format

The European Pharmacovigilance Congress will be a mixed event!

18-19 November | Virtual 9 am- 6 pm
21 November | APERITIF TIME, NH Milano Congress Centre 6 pm – 9 pm
22 November | Face to face, NH Milano Congress Center 9.30 am – 5 pm

APERITIF TIME – November 21 from 6 to 9 pm – NH Milano Congress
Reserve your place to meet and network with your colleagues, experts and opinion leaders!

This year the congress will include:
25 Topics
11 Virtual & Face-to-Face Parallel Sessions
25 Interactives Round Tables
2 Face to-Face Workshops
2 LECTIO Magistralis

Why attend?

  • Learn about the latest Pharmacovigilance trends and updates
  • Share experiences and solutions at a leading European event
  • Forge new collaborations with key decision makers
  • Networking through the virtual platform with Pharma Companies Delegates and Speakers

Who should attend?

  • Pharma, Biotech and Medical Devices Industries
  • Pharmacovigilance Associations
  • Regulatory Bodies
  • CROs and CMOs
  • Clinical Research Sites
  • Data Management Companies
  • Software Development Companies
  • University Faculties
  • PV Consultant Societies

TOPICS 2024

THEMATIC SESSIONS

18/11 – Virtual
– Biological Basis of Adverse Reactions (with focus on SCARs)
– Immunological Adverse Reactions
– Parallel– Comunicating Safety Information in the Digital Era (in progress)
– Signal Detection
– Risk Management
– Parallel – Risk Minimiztion Measures
– LECTIO Magistralis

19/11  – Virtual
– Authorities’ Assessment of PV Reports
– Real Word Data & Real Word Evidence
– Parallel – Evolving Landscape of Electronic Safety data in PV
– Manufacturing & PV Interfaces
– Parallel – Safety in Clinical Trials
– MedDRA (in progress)
– Parallel – Non EU PV Requirements
– LECTIO Magistralis

22/11 – Milan
– Evolving Pharmacovigilance Strategies
– Main Global and Local PV Updates
– F2F Workshop
– Practical Experience of Applying Artificial Intelligence in PV
– Audit & Inspections
and more parallel sessions coming…

November 18th 2024, Virtual


Welcome by the Chairperson of the Congress

09.00 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech

A Word from the Editor-in-Chief of Therapeutic Advances in Drug Safety - Eu PV Congress Media Partner

09.10 –  Arduino Mangoni, Strategic Professor in Clinical
Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia

SESSION 1 - Biological Basis of Adverse Reactions (with focus on SCARs)

09.15 – Chairperson – Giovanni FurlanWorldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.

09.20 – Severe cutaneous adverse drug reactions: epidemiological and pathophysiological considerations
Arduino MangoniStrategic Professor in Clinical Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia

09.40 – Understanding the Pathophysiological Mechanisms of SCARS: A Call for Harmonized Definitions and CIOMS Recommendations
Chia-Yu ChuProf. Department of Dermatology | National Taiwan University

10.00 – Biological basis of adverse drug reactions affecting the central nervous system
Georgios PapazisisProfessor of Clinical Pharmacology; Medical Director, Clinical Research Unit, School of Medicine | Aristotle University of Thessaloniki, Greece

10.20 – Round Table and Q&A Time
ModeratorG. Furlan
PanelistsA. MangoniC. Y. ChuG. Papazisis

10.50 – Coffee Break & networking

SESSION 2 - Immunological Adverse Reactions

11.10 – Chairperson – Mattia CalissanoHead of Pharmacovigilance | Orchard Therapeutics

11.15 – Assessing the global ,regional and personal immunogenity risk of biologic therapy
Anne de GrootCEO/CSO and Director | EpiVax

11.35 – Mitigation strategies for immunogenicity of biological therapeutic: Sometimes more is Better
Amy RosenbergSenior Director and Consultant, Immunology | EpiVax, Inc

11.55 – Round Table
ModeratorM. Calissano
PanelistsA. De GrootA. Rosenberg

12.30 – LUNCH

SESSION 3 - PARALLEL - Comunicating Safety Information in the Digital Era (in progress)

11.10 – Chairperson – Paola KrugerHead of Expert Patient | EUPATI (Europe an Patient’s Academy for Therapeutic Innovation)

11.20 – Safety Communication aspects of the ConcePTION Mobile App
Amanda Alexe,
 PV Policy and Liaison Lead, QPPV Office | Novartis

11.40 – Marco GrecoEuropean Patients’ Forum President (EPF) – TBC

12.00 – Panel Discussion

12.30 – LUNCH

SESSION 4 - Signal Detection

1.45 – ChairpersonMaddalena Lino, Safety Risk Lead Director | Pfizer

1.50 – Multi-modal data science for signal detection – What are the Challenges? What are the Opportunities
Natsiavas Pantelis
, Researcher (Grade C) | Institute of Applied Biosciences of Centre for Research and Technology Hellas (INAB|CERTH), Thessaloniki, Greece

2.10 – What is the role of Big Data and Artificial Intelligence in Pharmacovigilance?
Gianluca Trifirò
| Full Professor of Pharmacology Department of Diagnostics and Public Health | University of Verona

2.30 – Insights into recent safety observations associated with CART cell therapies
Vibha Jawa
| Executive Director for Biotherapeutics Bioanalysis in clinical Pharmacology, Pharmacometricsand Bioanalysis (NDB) organization | Bristol Myers Squibb

2.50 – Round Table and Q&A Time:
Moderator: M. Lino
Panelists: V. Jawa, N. Pantelis, G. Trifirò, F. De Gregorio | Shionogi Europe

3.20 – Coffee Break & Networking

SESSION 5 - PARALLEL - TBD

Maria Beatrice Panico | Principal Consultant | Scendea

SESSION 6 - Risk Management

3.40 – ChairpersonGlyn Belcher, CEO | PV Consultancy Ltd.

3.45 – Proposing Benefit-Risk Management Plans as the evolution of RMPs
Robert Massouh
Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk

4.05 – Pregnancy prevention – RMM effectiveness evaluation experience
Klaudija Marijanovic Barac,
 Sr. Director, EU&UK QPPV Deputy, Head Periodic Reports and Risk Management Unit | TEVA

4.25 – Pharmaceuticals in the environment: from Echopharmacovigilance to neurobehavioral studieson zebrafish
Giovanna PaoloneAssociate Professor of Pharmacology – Department of Diagnostics and Public Health | University of Verona

4.45 – Round Table and Q&A Time
Moderator: G. Belcher
Panelists: R. Massouh; K.M. Barac; G. Paolone

SESSION 7 - PARALLEL - Risk Minimization Measures

3.40 – ChairpersonHrvoje Macek, VP, Medical & Scientific Affairs, an Patient’s Academy for Therapeutic Innovation

3.45 – Design, implementation, and evaluation of risk minimization measures
Michael Von Forstner, Head of Safety Science | Sobi

4.05 – aRMM in pregnancy risk mitigation
Iva Kuliš, Principal Coordinator for Information in PV and Rational Pharmacotherapy, Dept for PV and Rational Pharmacotherapy| HALMED

4.25 – Challenges of benefit-risk assessment – when to trigger a referral procedure?
Barbara Kovačić Bytyqi, Head of Departement for Pharmacovigilance and Rational Pharmacotherapy | HALMED

4.45 – Round Table and Q&A Time
Moderator: H. Macek
Panelists: B. Kovačić Bytyqi; I. Kuliš; M. Von Forstner

SESSION 8 - LECTIO Magistralis

5.15 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech

5.20 – What are the cardiovascular risks of NSAIDs?
Nicholas MooreEmeritus Professor of Clinical Pharmacology | University of Bordeaux

5.45 – Q&A Time

6.00 – Closure of the Day

November 19th 2024, Virtual


Welcome by the Chairperson of the Congress

09.00 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech

SESSION 9 - Authorities' Assessment of PV Reports

09.10 – Chairperson – Mircea CiucaGlobal Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance

09.15 – PSUR assessment by The Malta Medicines Authority
John Joseph Borg | Director Post-Licensing | Malta
Medicines Authority

09.35 – Challenges in risk-benefit assessment
Roxana Dondera | Head of Pharmacovigilance and Risk Management Unit | National Agency for Medicine and Medical Devices of Romania

09.55 – Risk Management Plan for Radiopharmaceuticals
Sofia Trantza | Senior Pharmacovigilance Expert | PRAC member Greece

10.15 – Round Table and Q&A Time
ModeratorM. Ciuca
PanelistsJ.J. BorgR. DonderaS. Trantza

10.45 – Coffee Break & networking

SESSION 10 - Real Word Data & Real Word Evidence

11.05 – Chairperson – Lembit RagoSecretary-General | Council for International Organizations of Medical Sciences (CIOMS)

11.10 – RWD and RWE in regulatory decision making: CIOMS WG XIII Report
Lembit RagoSecretary-General |Council for International Organizations of Medical Sciences (CIOMS)

11.30 – From RWD to RWE – Teva experience
Željana Margan KoletićSenior Manager, Risk Management Plans (RMP) Team Leader | Teva

11.50 – Analysis of the nature and contributory factors of medication safety incidents following Hospital disharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-method study
Fatema Alqenae, Pharmacist | Kuwait – Winner EUPV 2023 Award

12.10 – Round Table and Q&A Time
ModeratorL. Rago
PanelistsZ.M. KoleticF. Alqenae

12.30 – LUNCH

SESSION 11 - PARALLEL - Evolving Landscape of Electronic Safety data in PV

11.05 – Chairperson – Jan PetracekCEO | iVigee

11.10 – Evolving Landscape of electronic safe data in PV in the EU
Calin Lungu | DDCS S.A., CEO

11.40 – TBD

12.00 – Panel Discussion

12.30 – LUNCH

SESSION 12 - Manufacturing & PV Interfaces

1.45 – Chairperson – Valentina ManciniSenior Director Pharmacovigilance QPPV | Shionogi Europe

1.50 – Looking for triggers: from the small signal to the bigger picture
AIFA Representative (tbc)

2.10 – NCE Early Development and Manufacturing : Idiosyncratic Reactions Risk Mitigation in Post Marketing
Terenzio Ignoni, SVP Quality and CMC | Gain Therapeutics

2.30 – Impact of Manufacturing Changes on Pharmacovigilance for Biological Products
Dina B. TresnanDisease Area Cluster Lead – Immunolo-Oncology; Safety Surveillance and Risk Management, Worldwide Safety | Pfizer

2.50 – Round Table
ModeratorTBC
PanelistsAIFA Representative (tbc); T. IgnoniD. Tresnan

SESSION 13 - PARALLEL - Safety in Clinical Trials

1.45 – ChairpersonMircea Ciuca, Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance

1.50 – Safety in clinical trials under the clinical trial regulation: state of play and first experience
Elena Prokofyeva, Head of safety in clinical trials unit, DG Post, FAMHP

2.10 – From SUSAR to risk via signal management
Mircea Ciuca | Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance

2.30/3 – Q&A Time

3.20 – Coffee Break

SESSION 14 - MedDRA (in progress)

3.40 – Chairperson Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech

3.45 – Adverse Event Grouping Strategies During Clinical Trial Analysis
Scott Proestel | VP, Medical Informatics | Medpace, Inc., former Senior Medical Officer | FDA

4.05 – Aoibhinn McDonnell | Safety Risk Lead, Director, Safety Surveillance and Risk Management | Pfizer

4.25 – Round Table
Moderator: M. Sardella
Panelists: S. Proestel; A. McDonnell

SESSION 15 - PARALLEL - Non EU PV Requirements

3.40 – ChairpersonMattia Calissano, Head of Pharmacovigilance | Orchard Therapeutics

3.45 – UK Pharmacovigilance Requirements: A Regulator’s Perspective
Fazil AfzalMedical Assessor at Medicines and Healthcare products Regulatory Agency (tbc)

4.05 – Elevating Pharmacovigilance in Saudi Arabia beyond Benchmarks to Innovation
Mayssa Abou Ghannam, Country Safety Team Lead, Saudi Arabia, Gulf, Pakistan, Afghanistan | Johnson & Johnson

4.25 – Comparison of RMM Approaches across EU, Japan and US
Robert MassouhHead of (PV) Risk Management and Benefit Risk Evaluation | Gsk

4.45 – Regulatory Requirements of Pharmacovigilance in India
Geeta ShanbhagVP Pharmacovigilance and MedicoRegulatory Affairs | Ipca Laboratories Ltd.

5.05 – Round Table
Moderator: M. Calissano
Panelists: F. Afzal; M. AbouGhannam; R. Massouh; G. Shanbhag

SESSION 16- LECTIO Magistralis

5.30 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech

5.30 – Pharmacovigilance – Where have we come from and where are we going?
Glyn Belcher | Senior Scientific Advisor | EUPV Congress

6.00 Closure of the Day

November 22nd, Face-to-Face in Milan


Welcome by the Chairperson of the Congress

09.20 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech

SESSION 17 - Evolving Pharmacovigilance Strategies

9.30 – Chairperson – Giovanni FurlanWorldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.

Panel Discussion:
Felix ArellanoSenior Vice President and the Global Head of Safety & Risk Management | Roche
Andrew Bate, VP Safety Innovation & Analytics | GSK
Marcin KrukDrug Safety Regional Head Europe , Africa, Middle East, Worlwide Medical & Safety | Pfizer Inc.
Sofia Trantza, Senior Pharmacovigilance Expert | PRAC Member Greece

10.40 – Coffee Break

SESSION 18 - Main Global and Local PV Updates

11.10 – Chairperson – Calin Lungu, CEO DDCS S.A.

11.15 – ICH E6 (R3)
AIFA Representative (tbc)

11.35 – Global and Local PV Regulatory Intelligence with AI: New Collection, Assessment, and Interpretation
Marcela Fialova, Chief Operating Officer | iVigee

11.55 – Global and Local PV requirements – Establishing and maintaining a compliant global PV system
Ilaria GrisoniExec. Dir., Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals

12.15 – Round Table
ModeratorC. Lungu
PanelistsAIFA RepresentativeI. GrisoniM. FialovaD. Marcozzi | Fidiapharma

12.40 – Award Ceremony for the selected PV article published in Therapeutic Advanced in Drug Safety 2023

12.50 – Lunch & Networking

PARALLEL SESSION: F2F Workshop

INTERACTIVE WORKSHOP

Topic 1
The Latest revisions of GVP guidelines on Risk Minimisation Measures and Definition – let’s navigate together through the updates
Mercedina del Papa, 
Strategic Advisor, EU QPPV Prime Vigilance

Topic 2
Pharmacovigilance between MA application and approval – challenges for sponsors transforming to MAH

Natalia Kalousova Kocankova, Senior Strategic Advisor, EU QPPV Office Director | PrimeVigilance

SESSION 19 - Practical Experience of Applying Artificial Intelligence in PV

2.00 – Chairperson Andrew BateVP Safety Innovation & Analytics | GSK

2.05 – MHRA experience in applications for AI in Pharmacovigilance
Phil TregunnoDeputy Director, Patient Safety Monitoring, Safety and Surveillance | MHRA

2.25 – Revolutionize Signal management with AI
Maurizio SessaAssociate Professor of Pharmacoepidemiology | University of Copenhagen

2.45 – AI in Pharmacovigilance at the Swedish Medical products Agency
Gabriel WestmanHead of Artificial Intelligence | Swedish Medical Products Agency

3.05 – Round Table
Moderator: A. Bate
Panelists: P. Tregunno; M. Sessa; V. Mancini | Shionogi Europe

3.30 – Coffee Break

SESSION 20 – Audit & Inspections

4.00 – Chairperson – Gian Nicola CastiglionePharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Past Head of Global Pharmacovigilance and EU-UK QPPV | Chiesi Farmaceutici S.p.A.

4.05 – AIFA Representative (tbc)

4.25 – Aurora María Rojo SanchísHead of GCP and GVP Inspectorate Spanish Agency of Medicines and Medical Devices (AEMPS)

4.45 – Iva Novak, Head of European Pharmacovigilance and EU QPPV | Teva

5.05 – Round Table
Moderator: G.N. Catiglione
Panelists: AIFA Representative; M. D’Antuono | Piramal , I. Novak; A.M. Rojo Sanchís

5.30 – Closure of the Congress

Scientific Advisory Group 2024 - In Progress...


Andrew Bate

Andrew Bate

VP, Head of Safety Innovation & Analytics | GSK

Glyn Belcher

Glyn Belcher

Senior Scientific Advisor | EU PV
Congress

Mattia Calissano

Mattia Calissano

Head of Pharmacovigilance | Orchard Therapeutics

Gian Nicola Castiglione

Gian Nicola Castiglione

Pharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Past Head of Global Pharmacovigilance and EU-UK QPPV | Chiesi Farmaceutici S.p.A.

Mircea Ciuca

Mircea Ciuca

Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance

Giovanni Furlan

Giovanni Furlan

Worldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.

Calin A. Lungu

Calin A. Lungu

DDCS S.A., CEO

Hrvoje Maček

Hrvoje Maček

VP, Medical & Scientific Affairs, EU QPPV | PrimeVigilance

Valentina Mancini

Valentina Mancini

Senior Director Pharmacovigilance, QPPV | Shionogi Europe

Jan Petracek

Jan Petracek

CEO | iVigee
Director, Institute of Pharmacovigilance

Marco Sardella

Marco Sardella

Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech

Speakers 2024 - In Progress...


John -Joseph Borg

John -Joseph Borg

Director Post-Licensing | Malta Medicines Authority

Roxana Dondera

Roxana Dondera

Head of Pharmacovigilance and Risk Management Unit | National Agency for Medicine and Medical Devices of Romania

Fazil Afzal

Fazil Afzal

Medical Assessor | Medicines and Healthcare products Regulatory Agency (MHRA)

Felix Arellano

Felix Arellano

Senior Vice President and the Global Head of Safety & Risk Management | Roche

Phil Tregunno

Phil Tregunno

Deputy Director, Patient Safety Monitoring, Safety and Surveillance | MHR

Scott Proestel

Scott Proestel

VP, Medical Informatics |Medpace,Inc., former Senior Medical Officer | FDA (tbc)

Glyn Belcher

Glyn Belcher

Senior Scientific Advisor | EU PV Congress

Lembit Rägo

Lembit Rägo

Secretary-General | Council for International Organizations of Medical Sciences (CIOMS)

Sofia Trantza

Sofia Trantza

Senior Pharmacovigilance Expert , PRAC member Greece

Calin A. Lungu

Calin A. Lungu

DDCS S.A., CEO

Terenzio Ignoni

Terenzio Ignoni

SVP Quality and CMC | Gain Therapeutics

Arduino Mangoni

Arduino Mangoni

Strategic Professor in Clinical Pharmacology | Flinders University; Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia

Andrew Bate

Andrew Bate

VP Safety Innovation & Analytics | GSK

Gabriel Westman

Gabriel Westman

Head of Artificial Intelligence | Swedish Medical Products Agency

Anne De Groot

Anne De Groot

CEO/CSO and Director | Epivax

Robert Massouh

Robert Massouh

Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk

Nicholas Moore

Nicholas Moore

Emeritus Professor of Clinical Pharmacology | University of Bordeaux

Chia Yu Chu

Chia Yu Chu

Prof. Department of Dermatology | National Taiwan University

Georgios	Papazisis

Georgios Papazisis

Professor of Clinical Pharmacology; Medical Director, Clinical Research Unit | School of Medicine, Aristotle University of Thessaloniki

Fabio De Gregorio

Fabio De Gregorio

Vice President, Head of Drug Safety Europe | Shionogi Europe

Mayssa AbouGhannam

Mayssa AbouGhannam

Country Safety Team Lead, Saudi Arabia, Gulf, Pakistan, Afghanistan | Johnson & Johnson

Marcin Kruk

Marcin Kruk

Drug Safety Regional Head Europe , Africa, Middle East, Worlwide Medical & Safety |Pfizer Inc.

Elena Prokofyeva

Elena Prokofyeva

Head of safety in clinical trials unit, DG Post, FAMHP

Amalia Alexe

Amalia Alexe

PV Policy and Liaison Lead, QPPV Office | Novartis

Amy	Rosemberg

Amy Rosemberg

Senior Director and Consultant, Immunology | EpiVax, Inc

Maurizio Sessa

Maurizio Sessa

Associate Professor of Pharmacoepidemiology | University of Copenhagen

Geeta Shanbhag

Geeta Shanbhag

VP Pharmacovigilance and Medico-Regulatory Affairs | Ipca Laboratories Ltd

Giovanna Paolone

Giovanna Paolone

Associate Professor of Pharmacology – Department of Diagnostics and Public Health | University of Verona

Alqenae Fatema

Alqenae Fatema

Pharmacist | University of Manchester –
Winner EUPV 2024 Award

Dina B. Tresnan

Dina B. Tresnan

Disease Area Cluster Lead -Immunolo-Oncology; Safety
Surveillance and Risk Management, Worldwide Safety | Pfizer

Ilaria Grisoni

Ilaria Grisoni

Executive Director, Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals

Vibha Jawa

Vibha Jawa

Executive Director | Bristol Myers Squibb

Klaudija Marijanovic Barac

Klaudija Marijanovic Barac

Sr. Director, EU&UK QPPV Deputy, Head Periodic Reports and Risk Management Centre | TEVA

Zeljana Margan Koletic

Zeljana Margan Koletic

Senior Manager, Risk Management Plans (RMP) Team Leader | Teva

Iva Novak

Iva Novak

Head of European Pharmacovigilance and EU QPPV | Teva

Marcela Fialova

Marcela Fialova

Chief Operating Officer | iVigee

Margherita D'Antuono

Margherita D'Antuono

EU-UK QPPV| Piramal Critical Care

Aurora María Rojo Sanchís

Aurora María Rojo Sanchís

Head of GCP and GVP Inspectorate Spanish Agency of Medicines and Medical Devices (AEMPS)

Marco Greco

Marco Greco

European Patients’ Forum President (EPF)

Maddalena Lino

Maddalena Lino

Safety Risk Lead Director | Pfizer

Daniela Marcozzi

Daniela Marcozzi

Head of Corporate Clinical Safety, Pharmacovigilance and R&D Compliance QP for Pharmacovigilance EU & UK, Graduated Plan Officer AMG 63a

Company Representative for Competent Health Authorities

Barbara Kovačić Bytyqi

Barbara Kovačić Bytyqi

Head of Department for Pharmacovigilance and Rational Pharmacotherapy | HALMED

Paola Kruger

Paola Kruger

Expert Patient | EUPATI (European Patient’s Academy for Therapeutic Innovation)

Iva Kuliš

Iva Kuliš

Principal Coordinator for Information in PV and Rational Pharmacotherapy, Dept for PV and Rational Pharmacotherapy | HALMED

Michael Von Forstner

Michael Von Forstner

Head of Safety Science| Sobi

Aoibhinn McDonnell

Aoibhinn McDonnell

Safety Risk Lead, Director, Safety Surveillance and Risk Management | Pfizer

Natalia Kalousova Kocankova

Natalia Kalousova Kocankova

Senior Strategic Advisor, EU QPPV Office Director | PrimeVigilance

Mercedina del Papa

Mercedina del Papa

Strategic Advisor, EU QPPV | Prime Vigilance

Sponsors & Media Partners 2024 - In Progress...

Baupharma

Silver Sponsor
Baupharma

Insuvia

Bronze Sponsor
Insuvia

iVigee

Gold Plus Sponsor
iVigee

Pharma D&S

Exhibitor
Pharma D&S

Accuvigil Private Limited

Sponsor
Accuvigil Private Limited

PrimeVigilance

Gold Sponsor
PrimeVigilance

Sage

Media Partner
Sage

Max Application

Exhibitor
Max Application

Become a sponsor

The European Pharmacovigilance Congress provides an excellent opportunity to get in touch with PV professionals and decision makers through a powerful virtual exhibition area. To sponsor the event, contact us.

Conference Venue

The European Pharmacovigilance Congress 2024 will be a mixed event:

Step 1

On November 18-19 the event will be VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:

  • Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
  • Visit the VIRTUAL EXHIBITION AREA and all the stands of our sponsors
  • Join Q&A times and round tables to discuss the current hot topics in the field
  • Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance

Step 2

Let’s finally meet face to face in Milan on November 22! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.

By plane

From Malpensa Airport:

    • take the bus to the central station, then the subway towards Assago Milanofiori Forum
    • take the express train from Malpensa to the Cadorna station, then the Green subway in the direction of Assago Milanofiori Forum.

From Linate Airport:
take the bus to San Babila station, then the subway towards Assago Milanofiori Forum.

By train

From Centrale or Cadorna train station, take green line subway to Assago Milanofiori Forum.

By tram

From Piazza del Duomo:
take the red subway line towards RHO FIERAMILANO and change at CADORNA. Take the green line towards ASSAGO MILANOFIORI FORUM and get off at the Assago Milanofiori Forum stop. Walk for about 7 minutes to reach the hotel.

All the past editions

Download brochures from previous editions of European Pharmacovigilance Congress 2024

Sign up for the conference

Face-to-Face (22/11/24)
Early bird until 18/10/2024*

400€
500€

Virtual (18-19/11/24)
Early bird until 18/10/2024*

600€
650€

Virtual + Face to Face (18-19/11/24 e 22/11/24)
Early bird until 18/10/2024*

750€
950€

* Hospitals, Universities and freelancers get a 40% discount on published prices (discounts cannot be combined).

Richiedi informazioni

Ask for information